139 related articles for article (PubMed ID: 36229265)
21. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Grisham RN; Iyer G; Garg K; Delair D; Hyman DM; Zhou Q; Iasonos A; Berger MF; Dao F; Spriggs DR; Levine DA; Aghajanian C; Solit DB
Cancer; 2013 Feb; 119(3):548-554. PubMed ID: 22930283
[TBL] [Abstract][Full Text] [Related]
22. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
[TBL] [Abstract][Full Text] [Related]
23. Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.
Xu Y; Bi R; Xiao Y; Tu X; Li M; Li A; Shan L; Zhou S; Yang W
Diagn Pathol; 2017 Dec; 12(1):87. PubMed ID: 29273082
[TBL] [Abstract][Full Text] [Related]
24. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract][Full Text] [Related]
25. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
Gershenson DM; Sun CC; Westin SN; Eyada M; Cobb LP; Nathan LC; Sood AK; Malpica A; Hillman RT; Wong KK
Gynecol Oncol; 2022 Jun; 165(3):560-567. PubMed ID: 35606067
[TBL] [Abstract][Full Text] [Related]
26. Low-grade serous carcinomas of the ovary contain very few point mutations.
Jones S; Wang TL; Kurman RJ; Nakayama K; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Shih IeM
J Pathol; 2012 Feb; 226(3):413-20. PubMed ID: 22102435
[TBL] [Abstract][Full Text] [Related]
27. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
[TBL] [Abstract][Full Text] [Related]
28. The mutational frequency of BRAF and KRAS in low-grade serous testicular neoplasms-a case series.
Gwiti P; Vereczkey I; Cundell D; Aslam S; Clench T; Csernák E; Götzer K; Braybrooke J; Sohail M; Melegh Z
Histopathology; 2017 Nov; 71(5):686-692. PubMed ID: 28543997
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of
Chui MH; Chang JC; Zhang Y; Zehir A; Schram AM; Konner J; Drilon AE; Da Cruz Paula A; Weigelt B; Grisham RN
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568720
[TBL] [Abstract][Full Text] [Related]
30. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
31. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
32. The status of epidermal growth factor receptor in borderline ovarian tumours.
Showeil R; Romano C; Valganon M; Lambros M; Trivedi P; Van Noorden S; Sriraksa R; El-Kaffash D; El-Etreby N; Natrajan R; Foroni L; Osborne R; El-Bahrawy M
Oncotarget; 2016 Mar; 7(9):10568-77. PubMed ID: 26870997
[TBL] [Abstract][Full Text] [Related]
33. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
[TBL] [Abstract][Full Text] [Related]
34. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
35. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
36. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic BRAF and KRAS mutations in endosalpingiosis.
Chui MH; Shih IM
J Pathol; 2020 Feb; 250(2):148-158. PubMed ID: 31576556
[TBL] [Abstract][Full Text] [Related]
38. BRAF
Turashvili G; Grisham RN; Chiang S; DeLair DF; Park KJ; Soslow RA; Murali R
Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
[TBL] [Abstract][Full Text] [Related]
39. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract][Full Text] [Related]
40. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]